CRDF - CIK 0001213037
Cardiff Oncology, Inc. (CRDF) reported revenue of $593.00K for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $593.00K | -13.2% |
| FY 2024 | $683.00K | +40.0% |
| FY 2023 | $488.00K | +26.4% |
| FY 2022 | $386.00K | +7.5% |
| FY 2021 | $359.00K | -1.9% |
| FY 2020 | $365.99K | +49.6% |
| FY 2019 | $244.63K | -35.3% |
| FY 2018 | $378.32K | -25.1% |
| FY 2017 |
Cardiff Oncology, Inc. (CRDF) reported revenue of $593.00K for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, Cardiff Oncology, Inc.'s revenue grew from $257.70K to $593.00K.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $505.40K |
| +32.6% |
| FY 2016 | $381.07K | +21.8% |
| FY 2015 | $312.81K | +11.6% |
| FY 2014 | $280.18K | +8.1% |
| FY 2013 | $259.25K | -42.4% |
| FY 2012 | $450.40K | +74.8% |
| FY 2011 | $257.70K | - |